Advanced searches left 3/3

Multiple Myeloma - Zenodo

Summarized by Plex Scholar
Last Updated: 13 April 2022

* If you want to update the article please login/register

Prevalence of the GFI1-36N SNP in Multiple Myeloma Patients and Its Impact on the Prognosis

Healthy Caucasians and 10-15% in patients with myelodysplastic syndrome and acute myeloid leukaemia predisposing GFI-36N carriers to these diseases have a 5-7% incidence. Since GFI1 is involved in B cell maturation and plasma cell formation, we investigated its incidence in patients with multiple myeloma, a haematological disorder characteristic of increased clonal PCs, we investigated its prevalence in patients with multiple myeloma. MM patients had a higher incidence than those in MDS and AML than controls, according to a study. Patients gaining 1q21 showed poor progress free survival.

Source link: https://zenodo.org/record/6414782


Epidemiology, genetics and treatment of multiple myeloma and precursor diseases

Multiple myeloma is a hematological malignancy triggered by plasma cell proliferation's clonal expansion. The incidence of MM globally is on the rise, with more than 140,000 people being diagnosed with MM per year. While 5-year survivors following a diagnosis of MM has increased from 28 percent in 1975 to 56% in 2012, the condition is still incurable. Ongoing research into the origins and early detection of MM, as well as the development of novel therapies such as immunotherapies, may have the ability to influence MM practice in the future.

Source link: https://zenodo.org/record/6413925

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions